Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Sterile Injection Manufacturing: SOP for Handling Packing Line Discrepancies – V 2.0

Posted on By

Sterile Injection Manufacturing: SOP for Handling Packing Line Discrepancies – V 2.0

Standard Operating Procedure for Handling Packing Line Discrepancies


Department Sterile Injection Manufacturing
SOP No. SOP/SIM/200/2025
Supersedes SOP/SIM/200/2022
Page No. Page 1 of 14
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To provide a standard procedure for the identification, investigation, documentation, and resolution of discrepancies encountered during packing operations in the sterile injectable manufacturing area. This ensures product integrity, traceability, and compliance with GMP requirements.

2. Scope

This SOP applies to

all packaging lines and related operations involving the packing of sterile injectable products, including vials, ampoules, and prefilled syringes in the sterile injection manufacturing department.

3. Responsibilities

  • Production Operator: Identify and report discrepancies immediately to the supervisor.
  • Packing Supervisor: Verify discrepancies, initiate investigation, and coordinate corrective action.
  • Quality Assurance (QA): Evaluate the impact of discrepancies, assist in investigation, and authorize product disposition.
  • Quality Control (QC): Support analytical testing if needed during discrepancy resolution.
  • Engineering/Maintenance: Investigate mechanical failures contributing to discrepancies.
See also  Sterile Injectable Manufacturing: SOP for Supplier Qualification of Raw Materials - V 2.0

4. Accountability

The Head of Production is accountable for ensuring the implementation of this SOP and addressing packing line discrepancies in coordination with QA.

5. Procedure

5.1 Identification of Discrepancies

  1. Discrepancies may include:
    • Incorrect labeling or missing labels
    • Unsealed or partially sealed units
    • Wrong batch number or expiry date
    • Mixed product batches
    • Incorrect quantity packed
    • Carton damage or missing leaflets
  2. Operators must immediately report any observed discrepancy to the supervisor.

5.2 Initial Action

  1. The supervisor shall:
    • Stop the line if necessary
    • Quarantine affected units
    • Notify QA for further assessment

5.3 Documentation and Verification

  1. Document the discrepancy in the Packing Line Discrepancy Log (Annexure-1).
  2. QA will inspect the quarantined units and surrounding area.
  3. Conduct reconciliation of labels, cartons, leaflets, and units packed to detect any mismatch.
  4. Record details such as product name, batch number, nature of discrepancy, quantity affected, and date/time observed.

5.4 Investigation and Root Cause Analysis

  1. QA and Production shall jointly perform a root cause analysis using tools like:
    • Fishbone (Ishikawa) diagram
    • 5 Whys technique
  2. If necessary, Engineering shall be involved to assess equipment malfunction.
  3. Capture investigation results in the Discrepancy Investigation Report (Annexure-2).
See also  Manufacturing Operations: SOP for Inert Gas Purging during Injectable Manufacturing - V 2.0

5.5 Corrective and Preventive Action (CAPA)

  1. Based on investigation outcome, QA shall recommend CAPA.
  2. Implement corrective measures immediately and document them.
  3. Preventive actions may include:
    • Operator training
    • Label redesign
    • Equipment calibration or maintenance
  4. Record CAPA actions in Annexure-3: CAPA Log.

5.6 Disposition and Line Clearance

  1. Only QA may approve product rework, rejection, or release.
  2. Line clearance shall be re-performed after resolving the discrepancy before resuming packing.

5.7 Documentation and Record Retention

  1. Maintain completed records of discrepancy logs, investigation reports, and CAPA logs.
  2. Store documents securely for a minimum of 5 years from batch release date.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • QC: Quality Control
  • CAPA: Corrective and Preventive Action
  • GMP: Good Manufacturing Practice

7. Documents

  1. Packing Line Discrepancy Log – Annexure-1
  2. Discrepancy Investigation Report – Annexure-2
  3. CAPA Log – Annexure-3
See also  Sterile Injectable Manufacturing: SOP for Cleaning of Laminar Flow Cabinets in Cleanrooms - V 2.0

8. References

  • WHO TRS 986 Annex 2 – GMP Guidelines for Pharmaceutical Products
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation Manufacturing Executive QA Executive Head QA
Department Production Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Packing Line Discrepancy Log

Date Batch No. Discrepancy Observed Quantity Affected Reported By
22/06/2025 BATCH-1021 Missing label on 5 vials 5 Rajesh Kumar

Annexure-2: Discrepancy Investigation Report

Date Batch No. Root Cause Investigated By Remarks
23/06/2025 BATCH-1021 Label roll misaligned Sunita Reddy Adjusted label sensor

Annexure-3: CAPA Log

CAPA No. Date Action Taken Responsible Status
CAPA-023 23/06/2025 Operator retraining and sensor alignment QA & Engineering Closed

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
20/03/2022 1.0 Initial Issue New SOP Head QA
24/06/2025 2.0 Expanded CAPA documentation process Annual Review Head QA
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: Common Audit Findings Related to SOP Non-Adherence
Next Post: Analytical Method Development: SOP for Tonicity Testing Method Development – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version